コンテンツにスキップ

英文维基 | 中文维基 | 日文维基 | 草榴社区

前田裕弘

リンクを追加
出典: フリー百科事典『ウィキペディア（Wikipedia）』

前田 裕弘（まえだ やすひろ、1955年3月9日 - ）は日本の医師。専門は血液内科、免疫内科。日本血液学会 血液専門医・指導医、日本エイズ学会 指導医、日本臨床免疫学会 免疫療法認定医。最終学歴は近畿大学。

来歴

[編集]

大阪府河内長野市生まれ。医学博士。1980年3月近畿大学医学部卒、同年6月同大学医学部第三内科学教室入局。同教室の講師に。その後、米国に渡りワシントン大学医学部病理学教室入局。日本に戻り近畿大学医学部の助教授を経て教授に。血液病理学、移植学、がん薬物療法、エイズ、免疫療法学に研鑽、現場に従事。

経歴

[編集]
  • 1980年03月　近畿大学医学部卒業
  • 1980年06月　近畿大学医学部第三内科学教室入局
  • 1982年04月　同教室助手
  • 1987年04月　京都大学医学部免疫研究施設Ｉ
  • 1989年04月　近畿大学医学部第三内科学教室講師
  • 1990年04月　米国ワシントン大学医学部病理学教室（ｾﾝﾄﾙｲｽ）
  • 2002年04月　近畿大学医学部血液・腎臓・膠原病内科助教授
  • 2008年10月　近畿大学医学部教授
  • 2011年04月　近畿大学医学部客員教授
  • 2011年04月　国立病院機構大阪南医療センター　がん疾患センター部長
  • 2016年04月　国立病院機構大阪南医療センター特命副院長併任
  • 2020年04月　医療法人浩仁会南堺病院　病院長
  • 2021年08月　医療法人敬任会南河内おか病院　副院長
  • 2023年06月　医療法人社団日翔会まえだクリニック　院長

所属学会

[編集]
  • 日本血液学会　血液専門医・指導医
  • 日本臨床血液学会　評議員
  • 日本臨床腫瘍学会　暫定指導医
  • 日本移植学会　認定医
  • 日本エイズ学会　認定医・指導医
  • 日本臨床免疫学会　免疫療法認定医
  • 日本感染症学会　インフェクションコントロールドクター
  • 日本再生医療学会　評議員
  • 日本HTLVーI学会　評議員
  • 日本癌学会
  • 日本内科学会
  • 欧州血液学会　
  • 米国血液学会
  • 国際実験血液学会

研究者

[編集]

論文

[編集]
  • Akinobu Tojo, Yasuhiro Maeda, et al.「A phase I/II study of nilotinib in Japanese patients with imatinib-resistant or-intolerant Ph+ CML or relapsed/refractory Ph+ ALL.」『International Journal of Hematology』. 89:679-688, 2009 [1]
  • Ohyashiki K, Maeda Y, et al.「Increased natural killer cells and decreased CD3(+) CD8(+) CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib.」『 British J Haematology』157:254-256, 2012 [2]
  • Kensuke Usuki, Yasuhiro Maeda, et al.「Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: a 36-month analysis of a phase I and II study.」『International journal of hematology』95:409-19, 2012
  • Kazunori Ohnishi, Yasuhiro Maeda, et al.「Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study.」『Cancer Science』103: 1071-1078, 2012
  • Yasuhiro Maeda, et al.「Improved drug adherence in patients with chronic myeloid leukemia in chronic phase by switching to second-generation tyrosin kinase inhibitors.」『Acta Haematologica』138 (3):140-142, 2017
  • Shin Fujisawa, Yasuhiro Maeda, et al.「Feasibility of the imatinib stop study in the Japanese clinical setting: delightedly overcome CML expert stop TKI trial (DOMEST Trial).」『International Journal of Clinical Oncology』2019 Apr; 24(4):445-453.
  • Yasuhiro Maeda, et al.「Clinical Importance of Drug Adherence during Tyrosine Kinase Inhibitor Therapy for Chronic Myelogenous Leukemia in Chronic Phase.」『Reports 2019』2, 25; doi:10.3390/reports2040025
  • Yasuhiro Maeda, et al.「Investigation about down-regulation of CD3 antigen on adult T cell leukemia cells. Flow Cytometry and Image Analysis for Clinical Applications.」『Elsevier Science Publishers B.V.』1991, p247-252
  • Mitsuhiro Matsuda, Yasuhiro Maeda, et al.「CD3 down-regulating factor in sera and culture supernatants of leukemic cells from the patients with adult T cell leukemia.」『British J. Haematol.』83: 212-217, 1993
  • Mitsuhiro Matsuda, Yasuhiro Maeda, et al.「Possible involvement of protein kinase C activation in down-regulation of CD3 antigen on adult T cell leukemia cells.」『British Journal of Haematology』86: 399-401, 1994
  • Yasuhiro Maeda, et al.「The down-regulation of CD3 antigen on Adult T cell Leukemia cells.」『Leukemia and Lymphoma』13: 249-256, 1994
  • Yasuhiro Maeda, et al.「13-cis retinoic acid Inhibits growth of adult T cell leukemia cells and causes apoptosis ; possible new indicator for retinoid therapy.」『Internal Medicine』35: 180-184, 1996
  • Yasuhiro Maeda, et al.「New Therapeutic effects of retinoid for adult T cell leukemia.」『BLOOD』88: 4726-4727, 1996
  • Jun-ichi Miyatake and Yasuhiro Maeda.「Retinoid induces growth inhibition of adult T-cell leukemia cells.」『Acta Medica Kinki University』22:111-121, 1997
  • Jun-ichi Miyatake and Yasuhiro Maeda.「Inhibition of proliferation and CD25 down-regulation by retinoic acid in human adult T cell leukemia cells.」『Leukemia』11: 401-407, 1997
  • Jun-ichi Miyatake, Yasuhiro Maeda, et al.「Thiol compounds rescue growth inhibition by retinoic acid on HTLV-I (+) T lymphocytes; possible mechnism of retinoic acid induced growth inhibition of adult T cell leukemia.」『Hematopathology and Molecular Hematology』11(2): 89-99, 1998
  • Jun-ichi Miyatake, Yasuhiro Maeda, et al.「Important role of thiol compounds to protect oxidative stress on HTLV-I(+) T lymphocytes.」『Leukemia Res』24(3): 265-266, 2000
  • Yasuhiro Maeda, et al.「Clinical application of all-trans retinoic acid (Tretinoin) for adult T cell leukemia.」『Br. J. Haematol』109: 677-678, 2000
  • Hiroyuki Nawata, Yasuhior Maeda, et al.「A mechanism of apoptosis induced by all-trans retinoic acid on adult T-cell leukemia cells: a possible involvement of the Tax/NF-kappaB signaling pathway.」『Leukemia Res』25(4): 323-331, 2001
  • Yasuhiro Maeda, et al.「All-trans retinoic acid reduced skin involvement of adult T-cell leukemia.」『Leukemia』18: 1159-1160, 2004
  • Terufumiu Yamaguchi, Yasuhiro Maeda, et al.「Dichotomy of all-trans retinoic acid inducing signals for adult T-cell leukemia.」『Leukemia』19:1010-7, 2005
  • Yasuhiro Maeda, et al.「Clinical efficacy of all-trans retinoic acid for treating adult T-cell leukemia.」『Journal of Cancer Reseaech of Clinical Oncology』134:673-677, 2008
  • Satomi Ueda, Yasuhiro Maeda, et al.「Influences of Epstein-Barr virus infection in adult T-cell leukemia.」『Hematology』13:154-162, 2008
  • Chikara Hirase, Yasuhiro Maeda, et al.「Hypersensitivity pf Ph-positive lymphoid cell lines tp rapamycin: Possible clinical application of mTOR inhibitor.」『Leukemia Res』33:450-459, 2009
  • Chikara Hirase, Yasuhiro Maeda, et al.「mTOR inhibition and adult T-cell leukemia.」『Leukemia and Lymphoma』50:645-647, 2009
  • Yasuhiro Maeda.「Retrovirus infection and retinoid. (Review).」『Acta Med Kinki Univ』34:1-13, 2009
  • Chen Z, Maeda Y, et al.「Thioredoxin-binding protein-2 (TBP-2/VDUP1/TXNIP) regulates T-cell sensitivity to glucocorticoid during HTLV-I-induced transformation.」『Leukemia』25:440-448, 2011
  • Yasuhiro Maeda, et al.「Senescence induction therapy for the treatment of adult T-cell leukemia.」『Leukemia and Lymphoma』52:150-152, 2011
  • Yasuhiro Maeda, et al.「Retrovirus infection and retinoid.」『T-cell leukemia. Edited by Olga Babusikova et al. InTECH』2011
  • Yasuhiro Maeda, et al.「Cellular senescence induction by retinoid on adult T-cell leukemia cells.」『Retrovirology 2011』2011, 8(Suppl 1):A31 (6 June 2011)
  • Yasuhiro Maeda, et al.「Effects of tamibarotene for treatment of adult T-cell leukemia.」『Ann Hematology』91:629-631，2012
  • Yasuyo Ohyama, Yasuhiro Maeda., et al.「Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T-cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies.」『Ann Hematology』93:169-71, 2014
  • Yasuhiro Maeda, et al.「Relationship between Cellular Senescence and Redox Potential on Adult T-Cell Leukemia Cells.」『Journal of Blood Research & Hematologic Diseases』 1:1.doi:10.4172/jbrhd.1000101
  • Yasuhiro Maeda, et al.「Adult T-Cell Leukemia and Retinoid.」『Journal of Hematology Research』2016.3:1-5
  • Yasuhiro Maeda, et al.「Deleted mutation of GSTT-1 gene in patients with MDS.」『Leukemia』12(12): 2039, 1998
  • Mitsuhiro Matsuda, Yasuhiro Maeda, et al.「Establishment of a myelodysplastic syndrome (MDS)/ secondary AML-derived T lymphoid cell line K2-MDS.」『Leukemia Res』24:103-108, 1999
  • Yoshiyasu Sumimoto, Yasuhiro Maeda, et al.「Establishment of a myeloid cell line, YM711, characterized by retinoid resistance.」『Leukemia and Lymphoma』39: 373-383, 2000
  • Hajime Miyazato, Yasuhiro Maeda, et al.「Detection of myeloperoxidase gene expression by in situ hybridization in a case of granulocytic sarcoma associated with AML-M0.」『Leukemia』16:1797-1799, 2001
  • Mitsuhiro Matsuda, Yasuhiro Maeda, et al.「Mitsuhiro Matsuda, Yasuhiro Maeda, et al.」『Int. J. Hematol』75: 335-336, 2002
  • Yasuhiro Maeda, et al.「Mutant type of glutathione S-transferase theta 1 gene homologue to mTOR in myelodysplastic syndrome :possible clinical application od rapamycin.」『Leukemia and Lymphoma』44: 1179-1185, 2003
  • Mitsuhiro Matsuda, Yasuhiro Maeda, et al.「CD34+ progenitors from MDS patients are unresponsive to SDF-1, despite high levels of SDF-1 in bone marrow plasma.」『 Leukemia』18: 1038-1040, 2004
  • Yasuyoshi Morita, Yasuhiro Maeda, et al.「A perforin/granzyme-positive MDS-derived T cell line, K2-MDS, induces apoptosis in CD34(+) cells through the fractalkine-CX3CR1 system.」『Clin Immunol』113:109-116, 2004
  • Mitsuhiro Matsuda, Yasuhiro Maeda, et al.「Extramedullary blast crisis derived from 2 different clones in the central nervous system and neck during complete cytogenetic remission of chronic myelogenous leukemia treated with Imatinib mesylate.」『International Journal of Hematology』81: 307-309, 2005
  • Yasuhiro Maeda, et al.「Possible molecular target therapy with rapamycin in MDS.」『Leukemia and Lymphoma』47: 907-911, 2006
  • Yasuhiro Maeda, et al.「Relationship between expression of mutant type glutathione S-transferase theta-1 gene and reactivity of rapamycin in myelodysplastic syndrome.」『Hematology』14:266-270, 2009
  • Yasuyoshi Morita, Yasuhiro Maeda, et al.「A case of chronic myelomonocytic leukemia who developed pericardial effusion during stably controlled leukocytosis.」『Internal Medicine』50:1737-1740, 2011　Retrovirology 8:100, 2011
  • Takahiro Kumode, Yasuhiro Maeda et al.「A case of secondary leukemia subsequent to myelodysplastic syndromes successfully treated with azacitidine.」『Case Reports in Medicine』Volume 2014, Article ID 793928, 3 pages
  • Yasuhiro Maeda, et al.「Transient eosinophilia by HIV infection.」『Ann. Hematol』79(2): 99-101, 2000
  • Yasuhiro Maeda, et al.「Herbs for HIV infection.」『Am J Hematol』70:263-264, 2002
  • Yasuhiro Maeda, et al.「All-trans retinoic acid attacks reverse transcriptase resulting in inhibition of HIV-1 replication.」『Hematology』12:263-266, 2007
  • Atsushi Sasakawa, Yasuhiro Maeda, et al.「Interleukin-8 in the pathogenesis of primary central nervous system lymphoma in association with HIV infection.」『Hematology』17:144-150, 2012
  • 前田裕弘「ステロイド投与中の高脂血症の治療」『診療と新薬』61：15-18, 2024
  • CiNii収録論文 - CiNii

著書

[編集]
  • 『血液疾患における多職種の関わり : ５つの症例から考えるチーム医療の実際』中外医学社、2020年4月7日。ISBN 978-4498225206
  • 『ウィルスとインターフェロン』慢性肝炎のインターフェロン療法(日本医学館) 1993年。
  • 『Investigation about down-regulation of CD3 antigen on adult T cell leukemia cells』Flow cytometry and Image analysis for Clinical Application Elsevier Science Publisher 1991
  • 『Signal transduction through FcεR2/Cd23 ; Induction of IL-2R/p55(Tac) by stimulation of Fc R2/Cd23』Luekocyte Typing Oxford University Press

脚注

[編集]

出典

[編集]
  1. ^ A phase I/II study of nilotinib in Japanese patients with imatinib-resistant or-intolerant Ph+ CML or relapsed/refractory Ph+ ALL.　Int J Hematol. 89:679-688, 2009
  2. ^ Increased natural killer cells and decreased CD3(+) CD8(+) CD62L(+) T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib.　British J Haematology 157:254-256, 2012
「https://ja-two.iwiki.icu/w/index.php?title=前田裕弘&oldid=102641295」から取得